AR048362A1 - Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos - Google Patents
Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismosInfo
- Publication number
- AR048362A1 AR048362A1 ARP050101295A ARP050101295A AR048362A1 AR 048362 A1 AR048362 A1 AR 048362A1 AR P050101295 A ARP050101295 A AR P050101295A AR P050101295 A ARP050101295 A AR P050101295A AR 048362 A1 AR048362 A1 AR 048362A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- sulfur
- oxygen
- independently selected
- Prior art date
Links
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 239000011593 sulfur Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 239000001301 oxygen Substances 0.000 abstract 4
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 abstract 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000005156 substituted alkylene group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
La presente se refiere a una sal farmacéuticamente aceptable del mismo, que ejerce una accion inhibitoria contra la proteína de transferencia del éster de colesterilo (CETP). Reivindicacion 1: Un compuesto caracterizado por la formula (1), en la cual R1 es un átomo de hidrogeno, un grupo alcoxicarbonilo opcionalmente sustituido, un grupo carbamoilo opcionalmente sustituido, un grupo alquilo opcionalmente sustituido, un grupo alcanoilo opcionalmente sustituido, un grupo heterocíclico monocíclico o bicíclico saturado o insaturado que contiene entre 1 y 4 heteroátomos seleccionados independientemente entre átomos de oxígeno, azufre y nitrogeno (el grupo heterocíclico es opcionalmente sustituido), o un grupo carbonilo heterocíclico monocíclico o bicíclico saturado o insaturado que contiene entre 1 y 4 heteroátomos seleccionados independientemente entre átomos de oxígeno, azufre y nitrogeno (el grupo heterocíclico es opcionalmente sustituido); R2 es un átomo de hidrogeno o un grupo opcionalmente sustituido; R3 es un átomo de hidrogeno o un grupo alquilo opcionalmente sustituido; R4 es un grupo alquileno opcionalmente sustituido; R5 es un grupo heterocíclico monocíclico o bicíclico saturado o insaturado que contiene entre 1 y 4 heteroátomos seleccionados independientemente entre átomos de oxígeno, azufre y nitrogeno, dicho grupo heterocíclico es opcionalmente sustituido; R6, R7 y R8 son independientemente un átomo de hidrogeno, un átomo halogeno, un grupo hidroxi, un grupo nitro, un grupo ciano, un grupo alquilo opcionalmente sustituido, un grupo alcoxi opcionalmente sustituido, un grupo alquil sulfonil oxi opcionalmente sustituido, un grupo mono- o di-alquilacrbamoilo opcionalmente sustituido, o un grupo amino opcionalmente sustituido; o R6, y R7, o R7 y R8 pueden combinarse en los extremos para formar un grupo alquileno, el grupo alquileno opcionalmente contiene entre 1 y 3 heteroátomos seleccionados independientemente átomos de nitrogeno, azufre y oxígeno, y pueden tener uno o más sustituyentes; y R10 es un anillo aromático que opcionalmente contiene entre 1 y 3 heteroátomos seleccionados independientemente entre átomos de oxígeno, azufre y nitrogeno (el anillo aromático está opcionalmente sustituido), o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004109551 | 2004-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048362A1 true AR048362A1 (es) | 2006-04-19 |
Family
ID=35064445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101295A AR048362A1 (es) | 2004-04-02 | 2005-04-01 | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7781443B2 (es) |
| EP (1) | EP1732924B1 (es) |
| JP (1) | JP4633731B2 (es) |
| KR (1) | KR100874623B1 (es) |
| CN (1) | CN100441579C (es) |
| AR (1) | AR048362A1 (es) |
| AU (1) | AU2005228291B2 (es) |
| BR (1) | BRPI0509588A (es) |
| CA (1) | CA2560008C (es) |
| IL (1) | IL178194A0 (es) |
| MX (1) | MXPA06011416A (es) |
| MY (1) | MY139887A (es) |
| NO (1) | NO20065012L (es) |
| NZ (1) | NZ550267A (es) |
| RU (1) | RU2356902C2 (es) |
| TW (1) | TWI345568B (es) |
| WO (1) | WO2005095395A2 (es) |
| ZA (1) | ZA200607782B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070208003A1 (en) | 2004-03-26 | 2007-09-06 | Bell Michael G | Compounds and methods for treating dyslipidemia |
| WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| ES2644450T3 (es) | 2004-12-31 | 2017-11-29 | Dr. Reddy's Laboratories Ltd. | Nuevos derivados de bencilamina como inhibidores de CETP |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2007048027A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| DK2149563T3 (en) | 2007-04-13 | 2015-02-02 | Kowa Co | Novel pyrimidine compound with dibenzylaminstruktur, and medicine comprising the compound |
| PE20090982A1 (es) | 2007-11-05 | 2009-08-13 | Novartis Ag | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) |
| US8759365B2 (en) * | 2007-12-03 | 2014-06-24 | Novartis Ag | Organic compounds |
| MX2011001887A (es) | 2008-08-22 | 2011-04-04 | Baxter Int | Derivados de bencil carbonato polimericos. |
| RU2012114770A (ru) * | 2009-09-04 | 2013-10-10 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| TR201816146T4 (tr) * | 2009-11-27 | 2018-11-21 | Adverio Pharma Gmbh | Meti̇l-{4,6-di̇ami̇no-2-[1-(2-florobenzi̇l)-1h-pi̇razolo[3,4-b]pi̇ri̇di̇n-3-i̇l]pi̇ri̇mi̇di̇n-5-i̇lmeti̇l}karbamatin farmasöti̇k etken madde olarak kullanima yöneli̇k olarak üreti̇lmesi̇ne yöneli̇k yöntem. |
| WO2012105574A1 (ja) * | 2011-01-31 | 2012-08-09 | 国立大学法人長崎大学 | 光学活性化合物又はその塩の製造方法 |
| JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物 |
| MX352074B (es) | 2011-09-27 | 2017-11-08 | Dr Reddys Laboratories Ltd | Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis. |
| JP6097225B2 (ja) * | 2012-01-06 | 2017-03-15 | 第一三共株式会社 | 置換ピリジン化合物の酸付加塩 |
| EP2753329B1 (en) | 2012-01-19 | 2017-08-09 | OncoTherapy Science, Inc. | 1,5-naphthyridine derivatives as melk inhibitors |
| JP2016504284A (ja) | 2012-11-16 | 2016-02-12 | バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 抗ウイルス性アザ糖を含有するヌクレオシド |
| CN110291072A (zh) | 2016-12-16 | 2019-09-27 | 巴斯夫欧洲公司 | 农药化合物 |
| WO2018220533A2 (ja) * | 2017-05-30 | 2018-12-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 光学活性化合物の製造法 |
| CN107245074B (zh) * | 2017-06-20 | 2019-04-09 | 牡丹江医学院附属红旗医院 | 用于治疗脑梗死的化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| BR0307332A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol |
| US20070208003A1 (en) * | 2004-03-26 | 2007-09-06 | Bell Michael G | Compounds and methods for treating dyslipidemia |
-
2005
- 2005-03-30 TW TW094109944A patent/TWI345568B/zh not_active IP Right Cessation
- 2005-03-30 MY MYPI20051440A patent/MY139887A/en unknown
- 2005-04-01 BR BRPI0509588-3A patent/BRPI0509588A/pt not_active IP Right Cessation
- 2005-04-01 MX MXPA06011416A patent/MXPA06011416A/es active IP Right Grant
- 2005-04-01 KR KR1020067020091A patent/KR100874623B1/ko not_active IP Right Cessation
- 2005-04-01 EP EP05728666A patent/EP1732924B1/en active Active
- 2005-04-01 CA CA2560008A patent/CA2560008C/en not_active Expired - Fee Related
- 2005-04-01 JP JP2006534488A patent/JP4633731B2/ja not_active Expired - Fee Related
- 2005-04-01 AU AU2005228291A patent/AU2005228291B2/en not_active Ceased
- 2005-04-01 CN CNB2005800104921A patent/CN100441579C/zh not_active Expired - Fee Related
- 2005-04-01 RU RU2006138597/04A patent/RU2356902C2/ru not_active IP Right Cessation
- 2005-04-01 NZ NZ550267A patent/NZ550267A/en unknown
- 2005-04-01 AR ARP050101295A patent/AR048362A1/es not_active Application Discontinuation
- 2005-04-01 WO PCT/JP2005/006895 patent/WO2005095395A2/en active Application Filing
-
2006
- 2006-09-18 ZA ZA200607782A patent/ZA200607782B/en unknown
- 2006-09-19 IL IL178194A patent/IL178194A0/en unknown
- 2006-09-27 US US11/527,556 patent/US7781443B2/en not_active Expired - Fee Related
- 2006-11-01 NO NO20065012A patent/NO20065012L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005095395A3 (en) | 2006-06-01 |
| BRPI0509588A (pt) | 2007-09-25 |
| RU2356902C2 (ru) | 2009-05-27 |
| US7781443B2 (en) | 2010-08-24 |
| US20070032485A1 (en) | 2007-02-08 |
| KR20060132966A (ko) | 2006-12-22 |
| CA2560008C (en) | 2010-06-01 |
| WO2005095395A2 (en) | 2005-10-13 |
| IL178194A0 (en) | 2006-12-31 |
| JP2007530444A (ja) | 2007-11-01 |
| KR100874623B1 (ko) | 2008-12-17 |
| JP4633731B2 (ja) | 2011-02-16 |
| NO20065012L (no) | 2006-12-28 |
| AU2005228291B2 (en) | 2008-06-26 |
| TWI345568B (en) | 2011-07-21 |
| EP1732924B1 (en) | 2012-11-28 |
| ZA200607782B (en) | 2008-02-27 |
| AU2005228291A1 (en) | 2005-10-13 |
| CA2560008A1 (en) | 2005-10-13 |
| NZ550267A (en) | 2009-08-28 |
| TW200536853A (en) | 2005-11-16 |
| CN1938301A (zh) | 2007-03-28 |
| EP1732924A2 (en) | 2006-12-20 |
| MY139887A (en) | 2009-11-30 |
| MXPA06011416A (es) | 2006-12-20 |
| CN100441579C (zh) | 2008-12-10 |
| RU2006138597A (ru) | 2008-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| AR107377A2 (es) | Compuestos derivados de tetrahidroquinolina | |
| PE20001093A1 (es) | 3-amino-4-aril-maleimidas como inhibidores de gsk-3 | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| AR059249A1 (es) | Compuesto amina trisustituido | |
| AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
| CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
| AR059248A1 (es) | Heterociclos nitrogenados y sus usos como inhibidores de aterosclerosis. composiciones farmaceuticas | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR057072A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
| AR035716A1 (es) | Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| TW200745117A (en) | Macrocylic inhibitors of hepatitis C virus | |
| ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| PE20200608A1 (es) | Nuevos derivados de azaquinolina | |
| AR074109A1 (es) | Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |